Play Drag View

Epi Axis

Client Epi Axis
Strategy & Consulting
Digital Analysis & Strategy
Business Consulting
Web Design
Website Design Mock-ups
Responsive Design
Website Banner Design
Website Development
Responsive Website Development
WordPress

EpiAxis Therapeutics is pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells (CSC). Specifically, that target is the nuclear bound lysine-specific demethylase 1 (LSD1) & its upstream regulator, the theta isoform of protein kinase C (PKC theta).The research identifying this target and the intellectual property (IP) that resulted from this was developed by Professor Sudha Rao and colleagues at the University of Canberra (UC), Australia.

The Company is focused initially on the prevention of metastatic breast cancer, with other CSC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later.

Check out our other works.

A UNEP Project
G20 Global Land Initiative
Wonder Paws
Empowering Women for Sustainable Peace – WPS-ASEAN
Greenstorm Global Photography Festival
UN-PEDRR
Dollar Curl Club
Recovery Through Repetition
EIA | Government of Iraq
UWeed